Opko Health, Inc. (OPK - Free Report) was a big mover last session, as its shares rose almost 6% on the day. The upside was driven by the FDA approval of Rayaldee for the treatment of secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease. This also led to far more shares changing hands than in a normal session. Yesterday’s rally reverses the downtrend for the company since Jun 2, as the stock is now down almost 8%.
Over the last 30 days, the company witnessed one positive and one negative estimate revision. Meanwhile, the Zacks Consensus Estimate moved higher, suggesting solid trading ahead. So make sure to keep an eye on this stock going forward to see if yesterday’s jump can turn into more strength down the road.
Opko Health has a Zacks Rank #3 (Hold) while its Earnings ESP is 0.00%.
A better-ranked stock in the med instruments space is CryoLife Inc. , sporting a Zacks Rank #1 (Strong Buy).
Is OPK going up? Or down? Predict to see what others think: Up or Down
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Opko Health, Inc. (OPK - Free Report) was a big mover last session, as its shares rose almost 6% on the day. The upside was driven by the FDA approval of Rayaldee for the treatment of secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease. This also led to far more shares changing hands than in a normal session. Yesterday’s rally reverses the downtrend for the company since Jun 2, as the stock is now down almost 8%.
Over the last 30 days, the company witnessed one positive and one negative estimate revision. Meanwhile, the Zacks Consensus Estimate moved higher, suggesting solid trading ahead. So make sure to keep an eye on this stock going forward to see if yesterday’s jump can turn into more strength down the road.
Opko Health has a Zacks Rank #3 (Hold) while its Earnings ESP is 0.00%.
A better-ranked stock in the med instruments space is CryoLife Inc. , sporting a Zacks Rank #1 (Strong Buy).
Is OPK going up? Or down? Predict to see what others think: Up or Down
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Get the latest research report on OPK - FREE